{"pmid":32334084,"title":"Incidence of coronavirus disease (COVID-19) and countries affected by malarial infections.","text":["Incidence of coronavirus disease (COVID-19) and countries affected by malarial infections.","Travel Med Infect Dis","Ahmed, Anwar E","32334084"],"journal":"Travel Med Infect Dis","authors":["Ahmed, Anwar E"],"date":"2020-04-26T11:00:00Z","year":2020,"_id":"32334084","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.tmaid.2020.101693","source":"PubMed","topics":["Prevention"],"weight":1,"_version_":1665071049631334400,"score":8.518259,"similar":[{"pmid":32326512,"title":"Epidemiology of Coronavirus COVID-19: Forecasting the Future Incidence in Different Countries.","text":["Epidemiology of Coronavirus COVID-19: Forecasting the Future Incidence in Different Countries.","This paper forecasts the future spread of COVID-19 by exploiting the identified lead-lag effects between different countries. Specifically, we first determine the past relation among nations with the aid of dynamic time warping. This procedure allows an elastic adjustment of the time axis to find similar but phase-shifted sequences. Afterwards, the established framework utilizes information about the leading country to predict the Coronavirus spread of the following nation. The presented methodology is applied to confirmed Coronavirus cases from 1 January 2020 to 28 March 2020. Our results show that China leads all other countries in the range of 29 days for South Korea and 44 days for the United States. Finally, we predict a future collapse of the healthcare systems of the United Kingdom and Switzerland in case of our explosion scenario.","Healthcare (Basel)","Stubinger, Johannes","Schneider, Lucas","32326512"],"abstract":["This paper forecasts the future spread of COVID-19 by exploiting the identified lead-lag effects between different countries. Specifically, we first determine the past relation among nations with the aid of dynamic time warping. This procedure allows an elastic adjustment of the time axis to find similar but phase-shifted sequences. Afterwards, the established framework utilizes information about the leading country to predict the Coronavirus spread of the following nation. The presented methodology is applied to confirmed Coronavirus cases from 1 January 2020 to 28 March 2020. Our results show that China leads all other countries in the range of 29 days for South Korea and 44 days for the United States. Finally, we predict a future collapse of the healthcare systems of the United Kingdom and Switzerland in case of our explosion scenario."],"journal":"Healthcare (Basel)","authors":["Stubinger, Johannes","Schneider, Lucas"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32326512","week":"202017|Apr 20 - Apr 26","doi":"10.3390/healthcare8020099","keywords":["covid-19","coronavirus","control strategies","dynamic time warping","epidemiology","forecasting","incidence","lead-lag effects","risk management"],"source":"PubMed","topics":["Prevention","Epidemic Forecasting"],"weight":1,"locations":["China","South Korea","United States","United Kingdom","Switzerland"],"countries":["Korea, Republic of","Switzerland","United Kingdom","China","United States"],"countries_codes":["KOR|Korea, Republic of","CHE|Switzerland","GBR|United Kingdom","CHN|China","USA|United States"],"_version_":1664996914874023936,"score":62.089207},{"pmid":32321540,"title":"COVID-19 and what pediatric rheumatologists should know: a review from a highly affected country.","text":["COVID-19 and what pediatric rheumatologists should know: a review from a highly affected country.","On March 11th, 2020 the World Health Organization declared COVID-19 a global pandemic. The infection, transmitted by 2019 novel coronavirus (2019-nCov), was first discovered in December 2019, in Wuhan, Hubei Province, and then rapidly spread worldwide. Italy was early and severely involved, with a critical spread of the infection and a very high number of victims. Person-to-person spread mainly occurs via respiratory droplets and contact. The median incubation period is 5 days. The spectrum of respiratory symptoms may range from mild to severe, strictly depending on the age of the patient and the underlying comorbidities.In children COVID-19 related disease is less frequent and less aggressive. In Italy 1% of positive cases are under 18 years of age, and no deaths have been recorded before 29 years of age. For patients affected by rheumatic disease, despite the concerns related to the imbalance of their immune response and the effect of immunosuppressive treatments, there are still few data to understand the real consequences of this infection. Major scientific societies have issued recommendations to help rheumatologists in caring their patients. Interestingly, some of the drugs mostly used by rheumatologists appear to be promising in critical COVID-19 infected patients, where the hyperinflammation and cytokine storm seem to drive to the multiorgan failure.Pediatric rheumatologists are expected to play a supporting role in this new front of COVID-19 pandemic, both as general pediatricians treating infected children, and as rheumatologists taking care of their rheumatic patients, as well as offering their experience in the possible alternative use of immunomodulatory drugs.","Pediatr Rheumatol Online J","Licciardi, Francesco","Giani, Teresa","Baldini, Letizia","Favalli, Ennio Giulio","Caporali, Roberto","Cimaz, Rolando","32321540"],"abstract":["On March 11th, 2020 the World Health Organization declared COVID-19 a global pandemic. The infection, transmitted by 2019 novel coronavirus (2019-nCov), was first discovered in December 2019, in Wuhan, Hubei Province, and then rapidly spread worldwide. Italy was early and severely involved, with a critical spread of the infection and a very high number of victims. Person-to-person spread mainly occurs via respiratory droplets and contact. The median incubation period is 5 days. The spectrum of respiratory symptoms may range from mild to severe, strictly depending on the age of the patient and the underlying comorbidities.In children COVID-19 related disease is less frequent and less aggressive. In Italy 1% of positive cases are under 18 years of age, and no deaths have been recorded before 29 years of age. For patients affected by rheumatic disease, despite the concerns related to the imbalance of their immune response and the effect of immunosuppressive treatments, there are still few data to understand the real consequences of this infection. Major scientific societies have issued recommendations to help rheumatologists in caring their patients. Interestingly, some of the drugs mostly used by rheumatologists appear to be promising in critical COVID-19 infected patients, where the hyperinflammation and cytokine storm seem to drive to the multiorgan failure.Pediatric rheumatologists are expected to play a supporting role in this new front of COVID-19 pandemic, both as general pediatricians treating infected children, and as rheumatologists taking care of their rheumatic patients, as well as offering their experience in the possible alternative use of immunomodulatory drugs."],"journal":"Pediatr Rheumatol Online J","authors":["Licciardi, Francesco","Giani, Teresa","Baldini, Letizia","Favalli, Ennio Giulio","Caporali, Roberto","Cimaz, Rolando"],"date":"2020-04-24T11:00:00Z","year":2020,"_id":"32321540","week":"202017|Apr 20 - Apr 26","doi":"10.1186/s12969-020-00422-z","keywords":["2019-ncov","covid-19","children","italy","respiratory syndrome","sars-cov-2"],"source":"PubMed","topics":["Prevention","Treatment"],"weight":1,"locations":["Wuhan","Hubei","Italy","Italy","multiorgan"],"countries":["China","Italy"],"countries_codes":["CHN|China","ITA|Italy"],"_version_":1664895932673556480,"score":56.6912},{"pmid":32325710,"title":"The COVID-19 Outbreak and Affected Countries Stock Markets Response.","text":["The COVID-19 Outbreak and Affected Countries Stock Markets Response.","This paper evaluates the short-term impact of the coronavirus outbreak on 21 leading stock market indices in major affected countries including Japan, Korea, Singapore, the USA, Germany, Italy, and the UK etc. The consequences of infectious disease are considerable and have been directly affecting stock markets worldwide. Using an event study method, our results indicate that the stock markets in major affected countries and areas fell quickly after the virus outbreak. Countries in Asia experienced more negative abnormal returns as compared to other countries. Further panel fixed effect regressions also support the adverse effect of COVID-19 confirmed cases on stock indices abnormal returns through an effective channel by adding up investors' pessimistic sentiment on future returns and fears of uncertainties.","Int J Environ Res Public Health","Liu, HaiYue","Manzoor, Aqsa","Wang, CangYu","Zhang, Lei","Manzoor, Zaira","32325710"],"abstract":["This paper evaluates the short-term impact of the coronavirus outbreak on 21 leading stock market indices in major affected countries including Japan, Korea, Singapore, the USA, Germany, Italy, and the UK etc. The consequences of infectious disease are considerable and have been directly affecting stock markets worldwide. Using an event study method, our results indicate that the stock markets in major affected countries and areas fell quickly after the virus outbreak. Countries in Asia experienced more negative abnormal returns as compared to other countries. Further panel fixed effect regressions also support the adverse effect of COVID-19 confirmed cases on stock indices abnormal returns through an effective channel by adding up investors' pessimistic sentiment on future returns and fears of uncertainties."],"journal":"Int J Environ Res Public Health","authors":["Liu, HaiYue","Manzoor, Aqsa","Wang, CangYu","Zhang, Lei","Manzoor, Zaira"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32325710","week":"202017|Apr 20 - Apr 26","doi":"10.3390/ijerph17082800","keywords":["covid-19","abnormal returns","investor sentiment","stock market indices"],"source":"PubMed","weight":0,"locations":["Japan","South Korea","Singapore","USA","Germany","Italy","GBR"],"countries":["Korea, Republic of","Singapore","United Kingdom","Japan","United States","Italy","Germany"],"countries_codes":["KOR|Korea, Republic of","SGP|Singapore","GBR|United Kingdom","JPN|Japan","USA|United States","ITA|Italy","DEU|Germany"],"_version_":1664996914929598465,"score":54.40604},{"pmid":32199877,"title":"Global epidemiology of coronavirus disease 2019 (COVID-19): disease incidence, daily cumulative index, mortality, and their association with country healthcare resources and economic status.","text":["Global epidemiology of coronavirus disease 2019 (COVID-19): disease incidence, daily cumulative index, mortality, and their association with country healthcare resources and economic status.","It has been 2 months since the first case of coronavirus disease 2019 (COVID-19) was reported in Wuhan, China. So far, COVID-19 has affected 85 403 patients in 57 countries/territories and has caused 2924 deaths in 9 countries. However, epidemiological data differ between countries. Although China had higher morbidity and mortality than other sites, the number of new daily cases in China has been lower than outside of China since 26 February 2020. The incidence ranged from 61.44 per 1 000 000 people in the Republic of Korea to 0.0002 per 1 000 000 people in India. The daily cumulative index (DCI) of COVID-19 (cumulative cases/no. of days between the first reported case and 29 February 2020) was greatest in China (1320.85), followed by the Republic of Korea (78.78), Iran (43.11) and Italy (30.62). However, the DCIs in other countries/territories were <10 per day. Several effective measures including restricting travel from China, controlling the distribution of masks, extensive investigation of COVID-19 spread, and once-daily press conferences by the government to inform and educate people were aggressively conducted in Taiwan. This is probably the reason why there was only 39 cases (as of 29 February 2020) with a DCI of 1 case per day in Taiwan, which is much lower than that of nearby countries such as the Republic of Korea and Japan. In addition, the incidence and mortality were correlated with the DCI. However, further study and continued monitoring are needed to better understand the underlying mechanism of COVID-19.","Int J Antimicrob Agents","Lai, Chih-Cheng","Wang, Cheng-Yi","Wang, Ya-Hui","Hsueh, Shun-Chung","Ko, Wen-Chien","Hsueh, Po-Ren","32199877"],"abstract":["It has been 2 months since the first case of coronavirus disease 2019 (COVID-19) was reported in Wuhan, China. So far, COVID-19 has affected 85 403 patients in 57 countries/territories and has caused 2924 deaths in 9 countries. However, epidemiological data differ between countries. Although China had higher morbidity and mortality than other sites, the number of new daily cases in China has been lower than outside of China since 26 February 2020. The incidence ranged from 61.44 per 1 000 000 people in the Republic of Korea to 0.0002 per 1 000 000 people in India. The daily cumulative index (DCI) of COVID-19 (cumulative cases/no. of days between the first reported case and 29 February 2020) was greatest in China (1320.85), followed by the Republic of Korea (78.78), Iran (43.11) and Italy (30.62). However, the DCIs in other countries/territories were <10 per day. Several effective measures including restricting travel from China, controlling the distribution of masks, extensive investigation of COVID-19 spread, and once-daily press conferences by the government to inform and educate people were aggressively conducted in Taiwan. This is probably the reason why there was only 39 cases (as of 29 February 2020) with a DCI of 1 case per day in Taiwan, which is much lower than that of nearby countries such as the Republic of Korea and Japan. In addition, the incidence and mortality were correlated with the DCI. However, further study and continued monitoring are needed to better understand the underlying mechanism of COVID-19."],"journal":"Int J Antimicrob Agents","authors":["Lai, Chih-Cheng","Wang, Cheng-Yi","Wang, Ya-Hui","Hsueh, Shun-Chung","Ko, Wen-Chien","Hsueh, Po-Ren"],"date":"2020-03-23T11:00:00Z","year":2020,"_id":"32199877","week":"202013|Mar 23 - Mar 29","doi":"10.1016/j.ijantimicag.2020.105946","keywords":["COVID-19","Coronavirus disease 2019","Country healthcare resources","Daily cumulative index","Disease incidence","Mortality"],"source":"PubMed","locations":["Wuhan","China","India","Japan","Italy","Iran"],"countries":["Italy","India","China","Japan","Iran, Islamic Republic of"],"countries_codes":["ITA|Italy","IND|India","CHN|China","JPN|Japan","IRN|Iran, Islamic Republic of"],"topics":["Mechanism","Prevention"],"weight":1,"_version_":1663352133611683840,"score":48.142433},{"pmid":32209383,"pmcid":"PMC7151357","title":"Herd immunity - estimating the level required to halt the COVID-19 epidemics in affected countries.","text":["Herd immunity - estimating the level required to halt the COVID-19 epidemics in affected countries.","J Infect","Kwok, Kin On","Lai, Florence","Wei, Wan In","Wong, Samuel Yeung Shan","Tang, Julian W T","32209383"],"journal":"J Infect","authors":["Kwok, Kin On","Lai, Florence","Wei, Wan In","Wong, Samuel Yeung Shan","Tang, Julian W T"],"date":"2020-03-27T11:00:00Z","year":2020,"_id":"32209383","week":"202013|Mar 23 - Mar 29","doi":"10.1016/j.jinf.2020.03.027","source":"PubMed","topics":["Epidemic Forecasting"],"weight":1,"_version_":1664638933394259970,"score":47.089367}]}